|
|
Blood, 1 September 2007, Vol. 110, No. 5, pp. 1612-1620.
Prepublished online as a Blood First Edition Paper on May 4, 2007; DOI 10.1182/blood-2006-10-053058.
 Previous Article | Next Article 
Submitted October 20, 2006
Accepted April 28, 2007
Genetic and pharmacologic evidence implicating the p85 , but not p85 , regulatory subunit of PI3K and Rac2 GTPase in regulating oncogenic KIT-induced transformation in acute myeloid leukemia and systemic mastocytosis
Veerendra Munugalavadla, Emily C. Sims, Jovencio Borneo, Rebecca J. Chan, and Reuben Kapur*
Dept of Pediatrics, Herman B Wells Center for Pediatric Research, Indiana University School of Medicine, Indianapolis, IN, United States
Dept of Medical & Molecular Genetics, Indiana University School of Medicine, Indianapolis, IN, United States
Dept of Molecular Biology & Biochemistry, Indiana University School of Medicine, Indianapolis, IN, United States
* Corresponding author; email: rkapur{at}iupui.edu.
Oncogenic activation loop KIT mutations are observed in acute myeloid leukemia (AML) and systemic mastocytosis (SM); however, unlike the KIT juxtamembrane mutants, the activation loop mutants are insensitive to Gleevec. Furthermore, as prior studies primarily utilized heterologous cell lines, the molecular mechanism(s) underlying oncogenic KIT-induced transformation in primary cells is poorly understood. We demonstrate that expression of KITD814V in primary hematopoietic stem/progenitor cells (HSC/Ps) and mast cell progenitors (MCps) induces constitutive KIT autophosphorylation, supports ligand-independent hyperproliferation, and promotes promiscuous cooperation with multiple cytokines. Genetic disruption of p85 , the regulatory subunit of class IA lipid kinase phosphoinositol-3-kinase (PI3K), but not of p85 , or genetic disruption of the hematopoietic cell-specific Rho GTPase, Rac2, normalizes KITD814V-induced ligand-independent hyperproliferation. Additionally, deficiency of p85 or Rac2 corrects the promiscuous hyperproliferation observed in response to multiple cytokines in both KITD814V-expressing HSC/Ps and MCps. Treatment of KITD814V-expressing HSC/Ps with a Rac inhibitor (NC23766) or with rapamycin showed a dose-dependent suppression in ligand-independent growth. Taken together, our results identify p85 and Rac2 as potential novel therapeutic targets for the treatment of KITD814V-bearing AML and SM.
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
This article has been cited by other articles:
|
|
|
|
 
L. Salazar, T. Kashiwada, P. Krejci, P. Muchowski, D. Donoghue, W. R. Wilcox, and L. M. Thompson
A novel interaction between fibroblast growth factor receptor 3 and the p85 subunit of phosphoinositide 3-kinase: activation-dependent regulation of ERK by p85 in multiple myeloma cells
Hum. Mol. Genet.,
June 1, 2009;
18(11):
1951 - 1961.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. Yan, S. Chen, Y. Zhang, X. Li, Y. Li, X. Wu, J. Yuan, A. G. Robling, R. Karpur, R. J. Chan, et al.
Rac1 mediates the osteoclast gains-in-function induced by haploinsufficiency of Nf1
Hum. Mol. Genet.,
April 1, 2008;
17(7):
936 - 948.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Tefferi, S. Verstovsek, and A. Pardanani
How we diagnose and treat WHO-defined systemic mastocytosis in adults
Haematologica,
January 1, 2008;
93(1):
6 - 9.
[Full Text]
[PDF]
|
|
|
|
|
